drugset / Trial / NCT01333904

Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118

NCT01333904 ↗

Phase 1 Completed 90 enrolled Pulmatrix Inc. Quotient Bioresearch · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to establish single and multiple dose safety in healthy subjects and subjects with mild chronic pulmonary obstructive disease (COPD). In addition, the study will evaluate preliminary proof of concept endpoints in COPD subjects such as biomarkers in sputum and mucociliary clearance.

Timeline

Start
2011-02
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PUR118 Unknown — Inhaled